Collaborations in clinical trials

EARL provides FDG-PET/CT accreditation for clinical trials initiated by scientific societies, (pharmaceutical) companies or hospitals/institutes in order to provide a minimum standard of PET/CT scanner performance. Accredited sites are able to compare, exchange and combine FDG-PET/CT findings including SUVs and also to collect data in a standardised manner.

Currently the following clinical trials are ongoing:

RegARd-C
Status: Recruiting
Study: Phase 2; Regorafenib Assessment in Refractory Advanced Colorectal Cancer
Condition: Advanced Chemorefractory Colorectal Adenocarcinoma
Intervention: Drug: regorafenib

Firstmappp
Status: Recruiting
Study: Phase 2; First Internatinal Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma
Condition: Pheochromocytoma and Paraganglioma
Intervention: Drug: Sunitinib 

EORTC 90111-24111
Status: Recruiting
Study: Phase 2; Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck
Condition: Carcinoma, Squamous Cell of Head and Neck
Intervention: Drug: Afatinib 

EORTC 22071-24071
Status: Withdrawn
Study: Phase 3; Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence
Condition: Head and Neck Cancer
Interventions: Biological: panitumumab; Drug: cisplatin; Drug: fluorouracil; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Procedure: quality-of-life assessment; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therap

BetaCure

Pertain Study


>> print article